Natera, Inc. (NTRA) announced Friday it's acquiring Foresight Diagnostics, a cancer diagnostics company specializing in detecting minuscule traces of cancer, for $275 million in cash. There's another $175 million on the table if Foresight hits certain revenue and reimbursement milestones, bringing the potential total to $450 million.
The deal is all about finding cancer earlier and earlier. Foresight has built its reputation around minimal residual disease (MRD) testing, which looks for tiny amounts of circulating tumor DNA in the bloodstream after treatment. Think of it as a surveillance system to catch cancer trying to sneak back.
"This acquisition reinforces Natera's position at the forefront of precision oncology," said Steve Chapman, Natera's CEO.
The Technology That Makes It Work
Foresight's secret sauce is its PhasED-Seq technology, which targets what are called phased variants in circulating tumor DNA. The company has reported performance with a limit of detection (LOD95) of 0.3 parts per million, with some detection happening below 0.1 ppm. To put that in perspective, we're talking about finding a needle in a haystack the size of a small city.
The transaction pairs Natera's established commercial infrastructure and personalized MRD testing capabilities with Foresight's specialized phased variant technology and expertise in lymphoma. It also builds on Natera's intellectual property portfolio covering tumor-informed and personalized MRD products, including phased variants, and should speed up MRD adoption in lymphoma and various solid tumor types.
Natera plans to integrate phased variants into its Signatera platform, which will enhance test performance across solid tumors. The enhanced version is immediately available for research use by biopharma and academic partners, with a clinical launch expected in 2026.
Why Lymphoma Matters
The acquisition capitalizes on Foresight's momentum in B-cell lymphomas, a substantial patient population with more than 75,000 new cases each year in the United States alone.
Earlier this year, research from Foresight provided the foundation for including ctDNA MRD testing into the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for diffuse large B-cell lymphoma. That's a big deal because NCCN guidelines essentially set the standard of care for cancer treatment in the U.S.
Foresight's CLARITY MRD assay for lymphoma is currently being used in three prospective MRD-driven clinical trials that inform treatment decisions for patients.
What Comes Next
Foresight CLARITY will join Natera's extensive MRD product portfolio and continue supporting clinical trials, translational research, and future applications.
"Foresight's phased variant technology and leadership in lymphoma complement Natera's strong capabilities in personalized MRD testing, improving the value we can deliver to patients, clinicians, biopharma partners, and the broader healthcare system," Chapman added.
Jake Chabon, Ph.D., Foresight's chief scientific officer and CEO, expressed enthusiasm about the combination. "Foresight's mission has always been to improve the lives of cancer patients worldwide through innovative diagnostics," he said. "As we join Natera, I'm deeply grateful to our employees, partners, and investors who have helped bring us to this moment. Together, we can realize this mission on a far greater scale, accelerating the pace of discovery across both hematologic and solid tumors."
Stock Movement: Natera shares were down 0.08% at $241.85 at the time of publication on Friday. The stock is trading near its 52-week high of $243.73.
